All In Biotech

Drug Trial Radar · NCT05526313

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Single-center, Dose-escalation Phase I Tolerability, Safety, Pharmacokinetics and Efficacy of Purinostat Mesylate (PM) for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant Hematologic Tumors Clinical Trials for Pharmacodynamic Evaluation

Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Aug 10, 2020

Primary completion

Sep 7, 2022

Study completion Mar 29, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purinostat mesylate for injection (PM) was the novel and highly potent Class I a and IIb HDAC-selective inhibitors. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice showed that the treatment of PM in each group reduced the proportion of peripheral blood tumor cells in mice. Therefore, PM has the potential to treat diffuse large B cell lymphoma. The results of in vitro enzymatic activity screening showed that PM has high inhibitory activity on HDAC tumors (including HDAC1, 2, 3, 8 subtypes) and type II HDACs (including HDAC6, 10 isoforms), which are closely related to tumors in the HDAC family. Therefore, the results of in vitro enzyme activity screening showed that the IC50 values of PM for inhibiting HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10 subtypes of HDAC class I and HDAC class IIb were 0.81, 1.4, 1.7, 3.8, 11.5, and 11 nM, respectively. However, the inhibitory activity of HDAC IIa and HDAC IV enzymes was low, and its IC50 values for HDAC4, HDAC5, HDAC7, HDAC9, and HDAC11 subtypes of HDAC IIa and HDAC IV were 1072, 426, 590, 622, and 3349 nM, respectively. These data means PM exist high selectivity for tumor-associated HDAC class I and HDAC IIb. Compared with the blank control group, the body weight of the tumor-bearing animals in each dose of PM group did not decrease seriously during the treatment process, and the animals were in good condition during the whole experiment, indicating that the PM is efficacy and safe. During the course of the experiment, the tumor cell population (GFP+, B220+) in the blood of the animals basically regressed after treatment with Prilistat hydrochloride. Research purposes: Main purpose: Observation of patients with relapsed or refractory hematological tumors (including but not limited to after standard therapy) mainly in patients with relapsed or refractory B cell-related tumors. Tolerability and safety of B-cell lymphoma, multiple myeloma, B-cell acute leukemia, T-cell lymphoma, T-cell acute leukemia) with disease progression or ineligible for standard therapy. To observe the dose-limiting toxicity (DLT) in patients with relapsed or refractory B cell-related tumors and hematological tumors, and determine its maximum tolerated dose (MTD), which is the maximum tolerated dose (MTD). Phase II clinical dosing schedule provides the basis. Secondary Purpose: To evaluate the pharmacokinetic parameters of patients with relapsed or refractory B-cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To evaluate the pharmacodynamics of patients with relapsed or refractory B cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To preliminarily observe the efficacy of Priinostat mesylate for injection in the treatment of patients with relapsed or refractory hematological tumors, mainly patients with B cell-related tumors.

Conditions

  • Diffuse Large B Cell Lymphoma,DLBCL

Interventions

  • Purinostat Mesylate 1.2mg/m^2Drug

    1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 2.4mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 4.0mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 6.0mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 8.4mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 11.2mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

  • Purinostat Mesylate 15mg/m^2Drug

    Take the medicine once on D1, D8, D11, D15.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Purinostat Mesylate Pharmacokinetics (PK):CmaxTime frame: 72hours
  2. Purinostat Mesylate Pharmacokinetics (PK):TmaxTime frame: 72hours
  3. Purinostat Mesylate Pharmacokinetics (PK):AUC0-72hTime frame: 72hours
  4. Purinostat Mesylate Pharmacokinetics (PK):AUC0-∞Time frame: 72hours
  5. Purinostat Mesylate Pharmacokinetics (PK):MRTTime frame: 72hours
  6. Purinostat Mesylate Pharmacokinetics (PK):VdTime frame: 72hours
  7. Purinostat Mesylate Pharmacokinetics (PK):t1/2Time frame: 72hours
  8. Purinostat Mesylate Pharmacokinetics (PK):CLz/FTime frame: 72hours
  9. Purinostat Mesylate Pharmacokinetics (PK):Vz/FTime frame: 72hours
  10. Purinostat Mesylate Pharmacokinetics (PK):KeTime frame: 72hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.